

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Lin, *et al.*
Serial No.: 08/182,183 Group Art Unit No.: 1644
Filed: May 23, 1994 Examiner: Robert C. Hayes
For: GLIAL CELL LINE-DERIVED
NEUROTROPHIC FACTOR
Docket No.: SYNE-225-E

RESPONSE TO NOTICE TO COMPLY AND AMENDMENT

Assistant Commissioner of Patents
Washington, D.C. 20231

Dear Sir:

In response to the Notice to Comply dated June 10, 2002 (Paper No. 54), Applicants hereby submit a revised Sequence Listing, the revised Sequence Listing in a computer readable form, a Statement pursuant to 37 C.F.R. §§ 1.821-1.825, and an amendment under 37 C.F.R. §§ 1.821-1.825. A shortened statutory period for response to the Notice to Comply was set, ending July 10, 2002. This response was filed prior to the expiration of that deadline. Applicants respectfully request that the following amendments be entered and the remarks considered.

EXPRESS MAIL CERTIFICATE

"Express Mail" mail
labeling number:

EL360687369US

Date of Deposit: July 10, 2002

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

S.L. ST. ANDREW

Printed Name

S.L. St. Andrew

Signature